Phase I Study of Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2017
At a glance
- Drugs GL ONC1 (Primary)
- Indications Malignant pleural effusion; Mesothelioma; Non-small cell lung cancer
- Focus Adverse reactions
- 27 Jan 2017 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.
- 27 Jan 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
- 27 Jan 2017 Status changed from recruiting to active, no longer recruiting.